Objectives: The detection of distant metastases is of major importance in management of head and neck squamous cell carcinoma patients.
| INTRODUCTION
Distant metastases are major determinants in both management and prognosis of head and neck squamous cell carcinoma (HNSCC) patients. 1 Patients diagnosed with distant metastases are generally considered incurable and will undergo palliative treatment. 2 Thus, futile extensive curative treatment can be prevented with careful screening for distant metastases during initial work-up. The time of diagnosis of distant metastasis (during pre-treatment diagnostic work-up or follow-up) may be important for overall survival.
The reported prevalence of distant metastases detected during pre-treatment diagnostic work-up in HNSCC patients varies from 2% to 26%, depending on the selected group of patients (eg stage of disease, locoregional control). [3] [4] [5] [6] [7] [8] [9] Due to the relatively low prevalence of distant metastases, it is important to identify patients who are most at risk of developing distant metastases and screen these patients with the best diagnostic techniques. High-risk factors have been identified (Table 1) . 10 The most frequent sites of distant metastases are the lungs, followed by the skeletal system and the liver.
11,12
18 F-fluorodeoxyglucose positron emission tomography ( 18 FDG PET) is able to detect distant metastases not detected by chest CT.
The combination of whole-body 18 FDG PET and contrast-enhanced (CE)-CT of the chest revealed a higher sensitivity than chest CT or whole-body 18 FDG PET as separate modalities. 13 As a result, integrated PET/CT has taken a major role in screening for distant metastases in head and neck cancer, as it combines functional (metabolic)
imaging (PET) with anatomical details (CT).
Several studies have reported on the value of 18 FDG PET/CT in screening for distant metastases in head and neck cancer, but with variable results. 14 Sources of heterogeneity comprise the patient spectrum (tumour type, stage and risk factors), as well as the reference standard (particularly the duration of follow-up) and locoregional control during follow-up. Cost-effectiveness analyses for the use of the 18 FDG PET/CT screening for distant metastases have
shown that its use results in overall cost savings by reducing the number of futile radical treatments. 15, 16 The aims of our study were to assess in a large cohort of HNSCC patients at increased risk of developing distant metastases:
(i) the accuracy of 18 FDG PET/CT to identify patients with distant metastases (ii) compare overall survival between patients diagnosed with distant metastases during initial screening and patients diagnosed with distant metastases during follow-up. follow-up was determined based on the time of detection of distant metastases during follow-up found in previous studies. 4, 8, 9, 19 Patients with distant metastases were treated with palliative intent, whereas patients were treated with curative intent after negative screening. If equivocal results remain equivocal after discussion in the multidisciplinary team, patients were treated with curative intent and imaging was repeated during follow-up.
| MATERIALS AND METHODS

| Patients and study design
As part of the pre-therapeutic work-up, all patients underwent panendoscopy, and contrast-enhanced CT and/or magnetic reso- Netherlands) were used to perform whole-body (from mid-thighs to skull vertex) 18 FDG PET/CT scans. 20, 21 The CT scans were low-dose non-contrast made for attenuation correction and anatomical correlation of PET, as well as CE-CT of the chest during the same session.
Patients fasted for at least 6 hours prior to scanning, which started 
Keypoints
• In head and neck squamous cell carcinoma patients with high risk factors screening for distant metastases by 18 FDG PET/CT should be used in daily clinical practice.
• There is room for improvement in screening for distant metastases in head and neck squamous cell carcinoma patients, because of the limited sensitivity of
approximately 60 minutes after intravenous 18 FDG administration.
The dose administered was 2.5 MBq/kg body weight (AE10%). Glucose levels were measured prior to 18 FDG administration. Image acquisition and reconstruction were performed according to the EANM 1.0 procedure guidelines. We scored what suspicion arose from the 18 FDG PET/CT using the written report of each scan. Most lesions suspicious of being malignant on 18 FDG PET/CT were confirmed using additional (follow-up)
imaging, endoscopic work-up and/or biopsy, using a rational approach. In some cases, findings of 18 FDG PET/CT were considered equivocal proof of distant metastases and consensus was reached not to perform additional work-up by the multidisciplinary team (giving the patient the benefit of the doubt). If tissue of both the primary process and the suspicious lesion outside of the head and neck region was obtained, and consisted of identical cell types, preferably a loss of heterozygosity analysis was performed.
| Statistical analysis
The reference (gold) standard used was follow-up of 12 months.
Sensitivity, specificity, positive and negative predictive values of the 18 FDG PET/CT for detection of distant metastases were calculated. 18 FDG PET/CT findings suspicious of being metastases were considered positive. Equivocal findings were scored as negative because patients with equivocal findings cannot be withheld from curative treatment. As in clinical practice, these patients were treated with curative intent. If no suspicious lesion or lesions suspicious of being either benign or second primary tumours were found, the scan was considered negative. The 18 FDG PET/CT findings were compared to the findings of further initial work-up and findings during follow-up.
We considered negative findings on 18 FDG PET/CT in patients who developed distant metastases during follow-up as being false negative, assuming these metastases were (subclinically) present at time of screening. In a separate analysis, these results were corrected for locoregional recurrence, as no distinction can be made between growth of subclinical metastases already present at the time of screening and reseeding of a locoregional recurrence after initial screening.
Overall survival (OS) was estimated using the Kaplan-Meier method and compared between groups using the log-rank test. The OS was measured from the time of initial 18 FDG PET/CT screening as well as from the time of detection of distant metastases during follow-up until the date of death. We compared the survival of the following groups:
patients without distant metastases vs those with distant metastases and patients diagnosed with distant metastases during initial work-up vs those diagnosed with distant metastases during follow-up.
Patients with second primary tumours outside the head and neck region, which were found during screening, were described separately. Significance was attributed to a P-value less than .05 (P < .05).
All calculations were performed using SPSS 22.0 for Windows.
| RESULTS
A total of 190 patients who underwent an 18 3.1 | Accuracy of 18 FDG PET/CT 
| Survival
Median OS in patients with distant metastases was significantly worse compared to patients without distant metastases (P < .001) (Figure 1) . OS from time of detection of patients in whom distant metastases were found during follow-up (median 6 months, 95% CI 0.5-11.5) when compared to patients diagnosed with distant metastases during screening (median 7 months, 95% CI 5.2-8.8) was not significantly different (P = .8). Median delay of diagnosis in the former group was 7 months (range 1-47 months). When comparing the OS from the time of initial screening, the patients diagnosed with distant metastases at initial screening (7 months, 95% CI 5.2-8.8) have a significantly worse expected survival (P = .001) compared to the group diagnosed during follow-up (16 months, 95% CI 11.9-20.1).
| Second primary tumours
In twenty-four patients (12.6%), the initial 18 FDG PET/CT was suspicious for second primary tumours outside of the head and neck region.
In ten patients, the detected lesions were suspicious of being either distant metastases or second primary tumours. Five of these lesions proved to be distant metastases through further work-up and were classified as true positive in Table 3 . Of the remaining 19 patients (all classified as true negative for distant metastases), work-up revealed 11 lesions (57.9%) to be second primary tumours, whereas in the other cases further work-up of the lesion showed no signs of malignancy. Table 4 depicts the number of lesions found in each organ (system).
| DISCUSSION
| Prevalence
In our cohort, 51 of 190 patients (26.8%) developed distant metastases, which is at the high end of the percentages found in previous studies. [3] [4] [5] [6] [7] [8] 12 This can be explained by our definition of the high-risk patient 10, 18 and our follow-up duration. We included also patients with a previous malignancy of the head and neck region and/or recurrent disease, whereas other studies included only patients with previously untreated head and neck cancer. 7, 9 The prevalence of distant metastases found by Haerle et al 8 4.2 |
FDG PET/CT
At first glance, the sensitivity of PET/CT to detect distant metastases in our study seems to be considerably lower than in other studies (Table 5) . 8, 9 This difference can partly be explained by the duration of follow-up: we considered all distant metastases identified during follow-up and negative on initial 
| Limitations
In the present study, we did not analyse the tumour burden of distant metastases. resected, and the distant sites are ablated (surgically or with radiation), a prolonged disease-free interval, and possible cure, may be achieved. 27 More research is needed to develop a new protocol for screening for distant metastases after implementation of the concept of treating oligometastases in HNSCC.
Another limitation of this study is potential bias in comparing survival of patients with distant metastases diagnosed at initial screening and follow-up due to different treatment regimens in these groups of patients. However, overall survival of patients with distant metastases detected during follow-up suggests that initial locoregional treatment with curative intent may be worthwhile in these patients with negative screening by PT/CT at initial work-up.
| CONCLUSION
Head and neck squamous cell carcinoma patients with low jugular lymph node metastases or regional recurrence have the highest risk of distant metastases. Patients diagnosed with distant metastases at initial screening have a significantly worse expected survival (from time of initial screening) compared to the group diagnosed during follow-up. In HNSCC patients with high-risk factors, 18 FDG PET/CT (including chest CE-CT) has a high negative predictive value for the detection of distant metastasis and should be part of the initial diagnostic work-up, although the sensitivity is limited when long-term follow-up is used as reference standard.
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